（进博故事）“进博宝宝”跑出审批“加速度”

Core Insights - The China International Import Expo (CIIE) has become a significant platform for multinational pharmaceutical companies to showcase their latest products and accelerate their market entry in China, exemplified by the rapid approval and commercialization of innovative medical devices and drugs [2][3][4]. Group 1: Product Launch and Approval Acceleration - The "CIIE acceleration" has enabled products like the Edward INSPIRIS RESILIA aortic valve to be approved for market in China within two months of its debut, benefiting over 3,000 patients [2]. - Novo Nordisk's insulin product, NovoRapid, achieved commercial launch and insurance approval in China within the same month of its first showcase at the CIIE, marking a significant milestone in the speed of drug approval processes [3]. - Boehringer Ingelheim's targeted biologic drug for generalized pustular psoriasis, the first of its kind, was launched in China ahead of other major markets, demonstrating the rapid development and approval capabilities in the Chinese market [4]. Group 2: Strategic Importance of CIIE - The CIIE serves as a "super showcase" for multinational pharmaceutical companies, allowing them to present their latest innovations and facilitating faster regulatory approvals in China [4]. - The event has contributed to a shift in the perception of China's regulatory environment, with instances of foreign regulatory bodies seeking information from Chinese approvals, indicating a growing recognition of China's role in global pharmaceutical innovation [4]. - The CIIE aligns with China's "Healthy China 2030" strategy, enhancing the collaboration between international pharmaceutical companies and the Chinese healthcare system, ultimately benefiting Chinese patients with access to cutting-edge medical technologies [4].